Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 1999

View Archived Issues

Once-daily oxybutynin assessed in urinary urge incontinence

Schering AG acquires rights to Nippon Shinyaku cerebrovascular agent

Licensing opportunity from NIH: MAb-ricin immunotoxin for focal movement disorders

Aviron's FluMist protects against influenza infection

Myogen achieves financing for oral enoximone pivotal trial

Cardioprotective efficacy of NHE-1 inhibitor is superior to that of IPC

Update on preclinical and clinical testing of R.W. Johnson's fibrinogen antagonist

Chemoprevention study will evaluate fenretinide in women at risk of ovarian cancer

Genentech and Inspire enter respiratory therapeutics collaboration

Milestone reached by Xoma in collaboration with Allergan

AVI BioPharma's cancer vaccine enters phase III development

CV Technologies' ginseng extract enters phase II for respiratory infection prophylaxis

Allergan's therapy for allergic conjunctivitis approved for U.S. marketing

Paladin will acquire Neuroscience Pharma and associated neurosteroid programs from Neurocrine

Novartis files regulatory dossiers for Zometa around the world

Cell Genesys withdraws from planned acquisition agreement

FDA gives the go-ahead to PhotoCure for phase I testing of Metvix

Millennium completes merger transactions with LeukoSite and Millennium BioTherapeutics

BLA filing for Campath announced

FDA approves depot form of Genentech's GH, efficacy of other formulations in increasing spine BMD

Celebrex approved by FDA for adjunctive therapy of FAP

Guilford's pipeline of PARP inhibitors continues to expand

Scios's new p38 MAP kinase inhibitors especially useful for cardiovascular disorders

WF-00144: novel bioactive compound for diabetes

Opioid receptor ligands from Novo Nordisk useful for vasomotor disturbances

New beta-lactams with activity against resistant staphylococci

Vitronectin receptor antagonists for bone disorders codeveloped at HMR and Genentech

Antitumor antibiotic induces human tumor cell apoptosis; probable mechanism of action unveiled

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...